uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Antonodimitrakis, PantelisORCID iD iconorcid.org/0000-0003-3121-5832
Alternative names
Publications (10 of 10) Show all publications
Clewemar, P., Hailer, N. P., Hailer, Y., Klar, J., Kindmark, A., Ljunggren, Ö. & Stattin, E.-L. (2019). Expanding the phenotypic spectrum of osteogenesis imperfecta type V including heterotopic ossification of muscle origins and attachments. Molecular Genetics & Genomic Medicine, 7(7), Article ID e00723.
Open this publication in new window or tab >>Expanding the phenotypic spectrum of osteogenesis imperfecta type V including heterotopic ossification of muscle origins and attachments
Show others...
2019 (English)In: Molecular Genetics & Genomic Medicine, ISSN 2324-9269, Vol. 7, no 7, article id e00723Article in journal (Refereed) Published
Abstract [en]

Background

Osteogenesis imperfecta (OI) is a clinical and genetic heterogeneous group of connective tissue disorders, characterized by bone fragility and a propensity to fracture.

Methods

In this report we describe the clinical phenotype of two patients, a 28‐year‐old woman and her mother (54 years old), both with a history of short stature and multiple fractures.

Results

Exome sequencing revealed the recurring IFITM5:c.‐14 C>T variant causing OI type V. Both patients had several fractures during childhood. CT‐scan and scintigraphy showed ossification of the origin and attachment of muscles and hypertrophic callus formation.

Conclusion

Ossification of the origin and attachment of muscles seems to be part of the phenotype in patients with OI type V.

Keywords
BRIL, heterotopic ossification, IFITM5, Osteogenesis imperfecta type V
National Category
Medical Genetics
Identifiers
urn:nbn:se:uu:diva-387239 (URN)10.1002/mgg3.723 (DOI)000475675000062 ()31099171 (PubMedID)
Available from: 2019-06-20 Created: 2019-06-20 Last updated: 2019-08-15Bibliographically approved
Crona, J., Norlén, O., Antonodimitrakis, P., Welin, S., Stålberg, P. & Eriksson, B. (2017). Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumors. Pancreas, 46(3), 441-441
Open this publication in new window or tab >>Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumors
Show others...
2017 (English)In: Pancreas, ISSN 0885-3177, E-ISSN 1536-4828, Vol. 46, no 3, p. 441-441Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
LIPPINCOTT WILLIAMS & WILKINS, 2017
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-321065 (URN)10.1097/MPA.0000000000000812 (DOI)000394448600077 ()
Available from: 2017-05-11 Created: 2017-05-11 Last updated: 2019-10-30Bibliographically approved
Antonodimitrakis, P. C., Olofsson, H., Grimelius, L., Sundin, A., Wassberg, C., Granberg, D., . . . Eriksson, B. (2017). Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion: a retrospective study. International Journal of Endocrine Oncology, 4(1), 9-22
Open this publication in new window or tab >>Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion: a retrospective study
Show others...
2017 (English)In: International Journal of Endocrine Oncology, Vol. 4, no 1, p. 9-22Article in journal (Refereed) Published
Abstract [en]

Aim: Vasoactive intestinal polypeptide producing neuroendocrine tumors are rare and cause severe hormonal symptoms. Patients/methods: Eighteen patients with vasoactive intestinal polypeptide producing neuroendocrine tumors were analyzed with reviews of medical records, radiology and tumor tissue specimens. Results: Twelve patients (67%) had liver metastases at diagnosis. Chemotherapy, somatostatin analogs and interferon were given as medical therapies. Streptozocin/5-fluorouracil produced an objective response in 40% of the evaluable patients. Somatostatin analogs gave a clinical/biochemical response in eight out of nine patients. Transarterial embolization of the liver and peptide receptor radionuclide therapy was given to refractory cases. Sixteen patients died during the observation period. The median overall survival from diagnosis was 102 months. Conclusion: Systemic chemotherapy and somatostatin analogs should be given in cases of advanced disease or for hormonal symptoms.

Keywords
chemotherapy, IFN-α, neuroendocrine tumors, pancreas, somatostatin analogs, survival, vasoactive intestinal polypeptide
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-342674 (URN)10.2217/ije-2016-0012 (DOI)000426222300003 ()
Available from: 2018-02-22 Created: 2018-02-22 Last updated: 2018-03-23Bibliographically approved
Crona, J., Norlén, O., Antonodimitrakis, P., Welin, S., Stålberg, P. & Eriksson, B. (2016). Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours. Journal of Clinical Endocrinology and Metabolism, 101(2), 445-452
Open this publication in new window or tab >>Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours
Show others...
2016 (English)In: Journal of Clinical Endocrinology and Metabolism, ISSN 0021-972X, E-ISSN 1945-7197, Vol. 101, no 2, p. 445-452Article in journal (Refereed) Published
Abstract [en]

CONTEXT:

As a group, neuroendocrine tumors (NETs) secrete many different peptide hormones, yet heretofore each NET patient is typically thought to produce at most one hormone that causes a distinct hormonal syndrome. A minority of patients have multiple hormones at diagnosis and may also develop secondary hormone secretion at a later stage.

OBJECTIVES:

The objectives of the study were to determine the frequency and to describe the impact of multiple and secondary hormone secretion in sporadic gasteroenteropancreatic NET patients.

DESIGN, SETTING, AND PARTICIPANTS:

This was a retrospective analysis of patients (n = 972) with gasteroenteropancreatic NET treated at Uppsala University Hospital, Uppsala, Sweden. Patients with the secretion of multiple hormones at diagnosis and/or those developing secondary hormone secretion during the disease course were identified and studied in further detail.

RESULTS:

In pancreatic NETs (PNETs), a total of 19 of 323 patients (6%) had secretion of multiple hormones at diagnosis, and 14 of 323 (4%) had secondary changes during the disease course. These phenomena occurred exclusively in patients with an advanced disease stage, and secondary hormones were detected in a close time span with progressive disease. Patients with secondary insulin hypersecretion had increased morbidity as well as reduced survival (P < .002). In contrast, multiple and secondary hormone secretion was rarely seen in NETs of the small intestine with 0 and 1 of 603 cases, respectively.

CONCLUSION:

Diversity of PNET hormone secretion either at diagnosis or during the disease course occurred in a minority of patients (9.3%). These phenomena had a major impact on patient outcome both through increased morbidity and mortality. Our results support that patients with metastatic PNETs should be monitored for clinical symptoms of secondary hormone secretion during the disease course.

National Category
Endocrinology and Diabetes Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-276291 (URN)10.1210/jc.2015-2436 (DOI)000378642700012 ()26672633 (PubMedID)
Available from: 2016-02-10 Created: 2016-02-10 Last updated: 2019-10-30Bibliographically approved
Antonodimitrakis, P., Sundin, A., Wassberg, C., Granberg, D., Skogseid, B. & Eriksson, B. (2016). Streptozocin and 5-FU for the treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity. Neuroendocrinology, 103(3-4), 345-353
Open this publication in new window or tab >>Streptozocin and 5-FU for the treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity
Show others...
2016 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 103, no 3-4, p. 345-353Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: In our center, the combination of streptozocin (STZ) and 5-fluorouracil (5-FU) has been used as the first-line treatment in the majority of patients with pancreatic neuroendocrine tumors (pNETs) over the past few decades. The objective of the current study was to assess the efficacy, prognostic factors and safety of the combination of STZ and 5-FU.

PATIENTS AND METHODS: Medical records and radiological reports of 133 patients with pNETs who received the combination of STZ and 5-FU during the period 1981-2014 were retrospectively evaluated.

RESULTS: Median survival from start of treatment was 51.9 months in the whole group. In the radiologically evaluable patients (n = 100) progression-free survival was 23 months. Complete response was reached in 3 patients (3%), partial response in 25 patients (25%), 64 patients (64%) had stable disease and 8 patients (8%) had progressive disease. In a multivariate analysis, surgery of the primary tumor and having a G3 tumor were significant positive and negative prognostic factors of survival from start of treatment, respectively. Having either a G3 tumor or stage IV tumor were significant prognostic factors for shorter progression-free survival. Chemotherapy had to be discontinued in 29 patients due to side-effects, of which kidney toxicity (mainly grade 1-2) was the most frequent.

CONCLUSION: As shown in recent reports, the combination of STZ and 5-FU is effective in the treatment of pNETs in terms of survival and radiological response, and has an acceptable toxicity profile.

National Category
Endocrinology and Diabetes Neurology
Identifiers
urn:nbn:se:uu:diva-261212 (URN)10.1159/000439086 (DOI)000375766500016 ()26279284 (PubMedID)
Available from: 2015-08-31 Created: 2015-08-31 Last updated: 2017-09-18Bibliographically approved
Ebeling-Barbier, C., Garske-Roman, U., Antonodimitrakis, P., Sandström, M., Nyman, R. & Granberg, D. (2015). Radioembolization with 90Y-Labelled Resin Microspheres in Patients with Liver Metastases from Neuroendocrine Tumors. Paper presented at 12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 11-13, 2015, Barcelona, SPAIN. Neuroendocrinology, 102(1-2), 136-137
Open this publication in new window or tab >>Radioembolization with 90Y-Labelled Resin Microspheres in Patients with Liver Metastases from Neuroendocrine Tumors
Show others...
2015 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 102, no 1-2, p. 136-137Article in journal, Meeting abstract (Other academic) Published
Keywords
radioembolization, neuroendocrine, liver metastases
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-266080 (URN)10.1159/000431385 (DOI)000361683500156 ()
Conference
12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 11-13, 2015, Barcelona, SPAIN
Available from: 2015-11-05 Created: 2015-11-05 Last updated: 2017-12-01Bibliographically approved
Karlsson, F., Antonodimitrakis, P. C. & Eriksson, O. (2015). Systematic screening of imaging biomarkers for the Islets of Langerhans, among clinically available positron emission tomography tracers. Nuclear Medicine and Biology, 42(10), 762-769
Open this publication in new window or tab >>Systematic screening of imaging biomarkers for the Islets of Langerhans, among clinically available positron emission tomography tracers
2015 (English)In: Nuclear Medicine and Biology, ISSN 0969-8051, E-ISSN 1872-9614, Vol. 42, no 10, p. 762-769Article in journal (Refereed) Published
Abstract [en]

Introduction: Functional imaging could be utilized for visualizing pancreatic islets of Langerhans. Therefore, we present a stepwise algorithm for screening of clinically available positron emission tomography (PET) tracers for their use in imaging of the neuroendocrine pancreas in the context of diabetes. Methods: A stepwise procedure was developed for screening potential islet imaging agents. Suitable PET-tracer candidates were identified by their molecular mechanism of targeting. Clinical abdominal examinations were retrospectively analyzed for pancreatic uptake and retention. The target protein localization in the pancreas was assessed in silico by -omics approaches and the in vitro by binding assays to human pancreatic tissue. Results: Six putative candidates were identified and screened by using the stepwise procedure. Among the tested PET tracers, only [C-11]5-Hydroxy-tryptophan passed all steps. The remaining identified candidates were falsified as candidates and discarded following in silico and in vitro screening. Conclusions: Of the six clinically available PET tracers identified, [C-11]5-HTP was found to be a promising candidate for beta cell imaging, based on intensity of in vivo pancreatic uptake in humans, and islet specificity as assessed on human pancreatic cell preparations. The flow scheme described herein constitutes a methodology for evaluating putative islet imaging biomarkers among clinically available PET tracers.

Keywords
Beta cell imaging, Islet imaging, Positron emission tomography, Pancreas, Islets of Langerhans, Endocrine
National Category
Endocrinology and Diabetes Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:uu:diva-264613 (URN)10.1016/j.nucmedbio.2015.06.004 (DOI)000361423700002 ()26138288 (PubMedID)
Funder
Swedish Child Diabetes FoundationSwedish Diabetes Association
Available from: 2015-10-27 Created: 2015-10-15 Last updated: 2017-12-01Bibliographically approved
Eriksson, B., Sundin, A., Wassberg, C., Skogseid, B. & Antonodimitrakis, P. (2014). Streptozocin and 5-fluorouracil treatment of pancreatic neuroendocrine tumors: efficacy, toxicity and prognostic factors. Wiener Klinische Wochenschrift, 126(S3), S145-S145, Article ID FP7.1.
Open this publication in new window or tab >>Streptozocin and 5-fluorouracil treatment of pancreatic neuroendocrine tumors: efficacy, toxicity and prognostic factors
Show others...
2014 (English)In: Wiener Klinische Wochenschrift, ISSN 0043-5325, E-ISSN 1613-7671, Vol. 126, no S3, p. S145-S145, article id FP7.1Article in journal, Meeting abstract (Other academic) Published
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-257481 (URN)000355221700017 ()
Available from: 2015-08-17 Created: 2015-07-02 Last updated: 2017-12-04Bibliographically approved
Crona, J., Fanola, I., Lindholm, D. P., Antonodimitrakis, P., Öberg, K., Eriksson, B. & Granberg, D. (2013). Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids. Neuroendocrinology, 98(2), 151-155
Open this publication in new window or tab >>Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids
Show others...
2013 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 98, no 2, p. 151-155Article in journal (Refereed) Published
Abstract [en]

Introduction: Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment so far have been disappointing. A previous study from our center indicated that temozolomide might be of value. Materials and Methods: All patients with progressive metastatic bronchial carcinoid treated with tennozolomide as monotherapy at our center between 2004 and 2010 (n = 31) were included in this retrospective study. 14 tumors were classified as typical and 15 as atypical carcinoids, whereas 2 tumors could not be classified. Temozolomide was given on 5 consecutive days every 4 weeks. Toxicity was evaluable in 28 of 31 patients, and 22 patients were evaluable by RECIST 1.1. Results: There were no complete responses. A partial response was seen in 3 patients (14%), stable disease in 11(52%) and progressive disease in 7 patients (33%). Median progression-free survival was 5.3 months and median overall survival was 23.2 months from the start of temozolomide. Toxcities grade 3-4 were noted in 4 patients, thrombocytopenia (n =3) and leukopenia (n = 1). Conclusion: Temozolomide as monotherapy shows activity in metastatic bronchial carcinoids. Regimens combining tennozolomide with other agents (e.g. capecitabine and/or bevacizumab, everolimus, radiolabeled somatostatin analogues) should be further studied in these patients. Copyright (C) 2013 S. Karger AG, Basel

Keywords
Bronchial carcinoid, Chemotherapy, Metastatic disease, Typical carcinoid, Atypical carcinoid
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-210761 (URN)10.1159/000354760 (DOI)000325735100007 ()
Available from: 2013-11-14 Created: 2013-11-14 Last updated: 2019-10-30Bibliographically approved
Antonodimitrakis, P., Wassberg, C., Gerovasileiou, S., Back, J., Hallgren, R. & Olsen, B. (2013). Fulminant hemophagocytic lymphohistiocytosis secondary to a reactivated EBV infection: A case report. Upsala Journal of Medical Sciences, 118(1), 42-45
Open this publication in new window or tab >>Fulminant hemophagocytic lymphohistiocytosis secondary to a reactivated EBV infection: A case report
Show others...
2013 (English)In: Upsala Journal of Medical Sciences, ISSN 0300-9734, E-ISSN 2000-1967, Vol. 118, no 1, p. 42-45Article in journal (Refereed) Published
Abstract [en]

Hemophagocytic lymphohistiocytosis (HLH) is an aggressive inflammatory syndrome that results from inappropriate activation of the immune system. HLH has a high mortality if not treated. We describe a case of a fulminant HLH, associated with a reactivation of an EBV infection. The patient responded well to steroid treatment.

Keywords
Epstein-Barr, hemophagocytic lymphohistiocytosis, reactivated infection, steroid treatment
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-196529 (URN)10.3109/03009734.2012.744122 (DOI)000314778900008 ()
Available from: 2013-03-13 Created: 2013-03-11 Last updated: 2017-12-06Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0003-3121-5832

Search in DiVA

Show all publications